Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation
Negative pressure wound therapy (NPWT) has become a powerful tool in wound bed preparation of complex wounds and is routinely used in various disciplines, including general surgery and plastic surgery.
NPWT involves the creation of a controlled subatmospheric pressure in the wound bed. The vacuum is generated by a pump and is distributed over the wound bed by a dressing (mostly a foam or gauze sponge). The therapy has several positive effects on the wound bed, such as improved local blood circulation, stimulation of granulation tissue formation and controlled evacuation of wound exudates. Standard negative pressure applied mostly varies between -120 mmHg and -130 mmHg.A new way of applying NPWT is the Engenex™ system using the Bio-Dome™ Wound Dressing, a specially engineered structure that forms a defined space above the surface of the wound. This space will maintain its size and integrity in the presence of negative pressure and wound fluids and thus effectively imposes strain on the underlying tissue. The material properties of the dressing permit moist wound healing while encouraging efficient removal of exudates. The contact material will not absorb fluid. It has been clinically shown that the Bio-Dome™ Wound Dressing is effective at growing granular tissue in the base of a wound at a safe low negative pressure of -75 mmHg, possibly reducing dressing ingrowth into the wound bed to a minimum.
Our intention is to evaluate NPWT by means of the Engenex™ pump and Bio- Dome™ Wound Dressing in 15 patients. Patients with large soft tissue defects will be examined by a plastic surgeon and if suitable for NPWT they will be treated with the Engenex™ NPWT system.
Before starting NPWT wounds will be evaluated and measured (length, width, depth, volume) if possible. Digital photos will be made and wound swabs will be taken for microbiological examination.Dressing changes will be performed twice weekly, on Monday and Thursday or on Tuesday and Friday. At each dressing change a wound will be re-evaluated and measured.
Other parameters to be noted will be, amongst others: pain, comfort, ease of use,material used, time needed for dressing change, etc.
The NPWT treatment will be carried on for maximum three weeks. During this period plastic surgeons will evaluate whether the wound is ready for surgical closure or not.
If surgical closure after 3 weeks is not yet an option possibility exists that NPWT will be continued.
Every wound will be followed up until complete wound healing after surgical closure.
All patients data will be recorded, secured, evaluated and analysed for both medical parameters and health economic parameters.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation|
- To evaluate safety and efficacy of NPWT with Engenex® [ Time Frame: at least 2 weeks ]
Following parameters are assessed:
- Adverse Events
- Wound size/volume and clinical aspects (odour, masceration): clinical evaluation, digital photography
- Degree of pain, measured by a numeric scale and the use of analgesics at each dressing intervention.
Control of Bioburden: Rate of critical colonization and/or infection
•% of patients with clinical infection requiring systemic antimicrobial therapy
- Monitoring of subject's comfort with the dressing in situ, evaluated by subject.
- Ease of use and dressing application and dressing removal, evaluated by health care personnel
- To provide instructions for optimal use of Engenex® [ Time Frame: at least 2 weeks ]
|Study Start Date:||February 2010|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
Device: Engenex™ pump and Bio-Dome™ Wound Dressing
Engenex™ pump and Bio-Dome™ Wound Dressing is used.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01107821
|Contact: Henk Hoeksema, PTemail@example.com|
|Contact: Jozef Verbelen, RN, MNfirstname.lastname@example.org|
|University Hospital Ghent||Recruiting|
|Principal Investigator: Stan Monstrey, MD, PhD|
|Principal Investigator:||Stan Monstrey, MD, PhD||University Hospital, Ghent|